Comment
doi: 10.1517/14656566.2010.497142.
Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)
Affiliations
- PMID: 20536293
- DOI: 10.1517/14656566.2010.497142
Item in Clipboard
Comment
Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)
Expert Opin Pharmacother.
2010 Sep.
Abstract
The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.
Comment on
-
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.Diabetes Care. 2010 Jun;33(6):1255-61. doi: 10.2337/dc09-1914. Epub 2010 Mar 9. Diabetes Care. 2010. PMID: 20215461 Free PMC article. Clinical Trial.
Similar articles
-
DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?Diabetes Metab. 2008 Feb;34 Suppl 2:S91-5. doi: 10.1016/S1262-3636(08)73400-1. Diabetes Metab. 2008. PMID: 18640591
-
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.Diabetes Care. 2007 Jun;30(6):1487-93. doi: 10.2337/dc06-2375. Epub 2007 Mar 12. Diabetes Care. 2007. PMID: 17353504 Clinical Trial.
-
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.Int J Clin Pract. 2006 Dec;60(12):1654-61. doi: 10.1111/j.1742-1241.2006.01196.x. Int J Clin Pract. 2006. PMID: 17109672 Review.
-
[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].J Fr Ophtalmol. 2003 Feb;26(2):131-6. J Fr Ophtalmol. 2003. PMID: 12660585 Clinical Trial. French.
-
Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.Cardiol Rev. 2006 Jul-Aug;14(4):205-11. doi: 10.1097/01.crd.0000223655.16253.e4. Cardiol Rev. 2006. PMID: 16788334 Review.
Cited by
-
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Diabetes Metab Syndr Obes. 2014 Jun 24;7:229-39. doi: 10.2147/DMSO.S35331. eCollection 2014. Diabetes Metab Syndr Obes. 2014. PMID: 25018644 Free PMC article. Review.
-
Adverse Effects of GLP-1 Receptor Agonists.Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10. Rev Diabet Stud. 2014. PMID: 26177483 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
